Valuation
- Market cap
- 42,501,000
- Revenue TTM
- $0
- Net income TTM
- $-6,380,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 900
- Avg volume
- 10,904
- Day's range
- $0.45 – $0.45
- Shares out
- 96,397,000
- Stochastic %K
- 34%
- Beta
- 0.42
- Analysts
- Strong Buy
- Price target
- $3.50
Company profile
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://nurexone.com
- Address
- 1 Adelaide Street East, Suite 801, Toronto, Canada
Latest news
No headlines yet.
